The impact of smoking on the platelets functional activity in patients with COPD

Objective: To compare the functional activity of platelets in patients with chronic obstructive pulmonary disease (COPD), depending on the commitment to smoking. Methods: Spirometry, estimated mMRC scale, CAT, the definition of spontaneous platelet aggregation (SPA) and aggregation induced by ADP-induced platelet aggregation (ADPIPA) and collagen-induced platelet aggregation (CIPA) (aggregation analyzer 2110 “Solar”). Clinical characteristics: The study involved 36 patients with COPD stage 2, at the age of 42 - 63 years (55.88 ± 3.65 years). Group I included 25 current smokers (24.15 ± 1.85 «pack-years"), group II - 11 non-smokers. The groups were equal according to severity of bronchoobstructive syndrome: FEV1 - 64.72 ± 6,12% of predicted, the value of the ratio of FEV1 / FVC - 65.34 ± 4 36%. All patients were included in Category B (GOLD, 2011) according to the integrated assessment of symptoms (mMRC ≥2, CAT> 10, CCQ≥1). Results: Patients of Group I showed an increase in SPA up to 28.26±3.45% (n = 20.0 ± 2.5%), ADPIPA - to 82.23 ± 5.42 s, CIPA - 83.14 ± 4.67 s. (N = 58.0-74.0 sec.). In Group II, SPA was 21.58 ± 2.34%, ADPIPA -77.24 ± 4.22c, CIPA - 76.52 ± 5.14sec. Functional activity of platelets was above normal in both groups, with significantly higher levels of spontaneous and induced platelet aggregation in group I (p Conclusion: COPD patients showed an increase in the functional activity of platelets. Smoking contributes to changing of vascular-platelet hemostasis and increases the risk of thrombotic complications in patients with COPD. Stopping smoking can reduce the risk of thrombosis in patients with COPD. People, who continue to smoke need to include desagregants in treatment.